U.S. market Open. Closes in 4 hours 25 minutes

ZTS | Zoetis Inc. Stock Overview

(Stock Exchange: NYSE)
Day's Range 174.55 - 176.77
52 Week Range 144.80 - 201.92
Beta 0.98
Implied Volatility 23.28%
IV Rank 8.15%
Day's Volume 398,602
Average Volume 2,080,928
Shares Outstanding 451,165,000
Market Cap 79,683,859,970
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO Date 2013-02-01
Valuation
Profitability
Growth
Health
P/E Ratio 33.20
Forward P/E Ratio 32.63
EPS 5.32
1YR Price Target 225.00
Dividend Yield 0.98%
Dividend Per Share 1.74
Dividend ExDate 2023-07-20
Dividend PayDate 2023-09-01
Employees 14,100
Country USA
Website ZTS
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
ZTS's peers: BHC, EBS, TAK, TEVA, VTRS, PETQ, NBIX, HLN, ITCI, CTLT, AMPH, ALVO, ASRT, ELAN
*Chart delayed
Analyzing fundamentals for ZTS we got that it has average fundamentals where Valuation is considered to be overvalued, Profitability is stunning wealthy, Growth is on medium level and Health is confidently strong. For more detailed analysis please see ZTS Fundamentals page.

Watching at ZTS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ZTS Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙